Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis
Inflammatory Bowel Diseases · 01.05.2026 · 32 (5) · 954-962
DOI: 10.1093/ibd/izaf319 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 12.02.2026. Verfasst von David T Rubin und 18 weiteren Autor:innen. Beteiligte Einrichtung: University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, United States. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Indans, Multiple Sclerosis, Relapsing-Remitting, Oxadiazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Princeton, NJ, United States, Bristol Myers Squibb, Peloton Advantage.
Abstract (Originalsprache)
Background
Ozanimod is a once-daily oral selective sphingosine 1-phosphate receptor modulator approved for the treatment of moderately to severely active ulcerative colitis (UC) or relapsing multiple sclerosis (RMS). Previous analyses in both indications demonstrated favorable long-term safety profiles of ozanimod. Here we report an integrated analysis of the long-term safety of ozanimod in patients with UC or RMS.
Methods
Data were pooled in patients with UC who received ozanimod in phase 2, phase 3, and open-label extension (OLE) trials and in patients with RMS who received ozanimod in an OLE trial after completing any phase 1-3 parent trial. Safety assessments included treatment-emergent adverse events (TEAEs) and laboratory abnormalities.
Results
Overall, 3652 patients with UC or RMS had 16 144 patient-years (PY) of ozanimod exposure over 10 years of follow-up. The most common TEAEs were nasopharyngitis, headache, and coronavirus disease 2019. Rates of TEAEs leading to treatment discontinuation (1.4/100 PY) and TEAEs of special interest, including serious infections (1.0/100 PY), herpes zoster (0.5/100 PY), malignancies (0.4/100 PY), bradycardia (0.1/100 PY), sinus bradycardia (0.04/100 PY), complete atrioventricular block (0.01/100 PY), and macular edema (0.1/100 PY), were low. No serious hepatic events or Hy’s law cases occurred. Absolute lymphocyte count of < 200 cells/µL was not temporally associated with serious or opportunistic infections.
Conclusions
Long-term exposure to ozanimod is well tolerated in patients with moderate to severe UC or RMS, confirming the previously established safety profile of ozanimod. Clinical Trial Registry NCT01647516; NCT02435992; NCT02576717
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, United States.
- Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
- Sapporo Medical University, Sapporo, Japan.
- Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- Center for Crohn's Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, GA, United States.
- Department of Gastroenterology, Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russia.
ORCID-Profile: David T Rubin, Silvio Danese
Förderung
- Bristol Myers Squibb, Princeton, NJ, United States
- Bristol Myers Squibb
- Peloton Advantage
- OPEN Health company
Zitieren
APA
Rubin, D. T., Danese, S., Nakase, H., Ungaro, R. C., Wolf, D. C., Alekseeva, O., Petersen, A., Liu, Z., Mehra, D., Jain, A., Osterman, M. T., Krakovich, A., Riolo, J. V., DeBoer, E., Appio, J., Sinh, P., Cree, B. A. C., Cohen, J. A., & Irving, P. (2026). Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. Inflammatory Bowel Diseases, 32(5), 954-962. https://doi.org/10.1093/ibd/izaf319
Vancouver
Rubin DT, Danese S, Nakase H, Ungaro RC, Wolf DC, Alekseeva O, et al. Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. Inflammatory Bowel Diseases. 2026;32(5):954-962. doi:10.1093/ibd/izaf319
BibTeX
@article{Rubin2026,
author = {Rubin, David T and Danese, Silvio and Nakase, Hiroshi and Ungaro, Ryan C and Wolf, Douglas C and Alekseeva, Olga and Petersen, AnnKatrin and Liu, Zhaohui and Mehra, Dimpy and Jain, Anjali and Osterman, Mark T and Krakovich, Anthony and Riolo, Jon V and DeBoer, Erik and Appio, James and Sinh, Preetika and Cree, Bruce A C and Cohen, Jeffrey A and Irving, Peter},
title = {Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {5},
pages = {954--962},
doi = {10.1093/ibd/izaf319}
}
EUVIMED